NCT00015977View on ClinicalTrials.gov

Vaccine Therapy Plus Interleukin-12 in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy

PHASE2CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

November 30, 2001

Primary Completion Date

March 31, 2003

Study Completion Date

January 31, 2005

Conditions
Prostate Cancer
Interventions
BIOLOGICAL

PSA prostate cancer vaccine

BIOLOGICAL

recombinant interleukin-12

Trial Locations (1)

60637-1470

University of Chicago Cancer Research Center, Chicago

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

University of Chicago

OTHER

NCT00015977 - Vaccine Therapy Plus Interleukin-12 in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy | Biotech Hunter | Biotech Hunter